Efficacy and influencing factors of 3-N-Butylphthalide-trazodone combination in managing post-ischemic stroke depression

Figure 1 Analysis of National Institutes of Health Stroke Scale, Barthel Index, and 17-item Hamilton Depression Rating Scale scores. A: Pre- and post-treatment National Institutes of Health Stroke Scale scores across groups; B: Barthel Index scores pre- and post-treatment; C: Pre- and post-treatment 17-item Hamilton Depression Rating Scale in two groups. ^aP < 0.05, ^bP < 0.01 within-group comparison vs pre-treatment, ^cP < 0.05 vs the reference group. NIHSS: National Institutes of Health Stroke Scale; HAMD17: 17-item Hamilton Depression Rating Scale.

Figure 2 Comparative analysis of serum neurotransmitters. A: 5-hydroxytryptamine alterations (pre- vs post-treatment) in two groups; B: Dopamine changes pre- and post-treatment; C: Pre- and post-treatment norepinephrine levels. ^aP < 0.05 and ^bP < 0.01 vs pre-treatment value, ^cP < 0.05 vs the reference group. 5-HT: 5-hydroxytryptamine; DA: Dopamine; NE: Norepinephrine.